Associated Papers
Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations.
Li X et al.
Pharmacogenomics and Personalized Medicine, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
Lee HH et al.
Molecular Cancer Therapeutics, 2015
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
23311897 (PubMed )
Supplement: gm405-S1.PDF
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC et al.
British Journal of Clinical Pharmacology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Pharmacogenetic pathway analysis of docetaxel elimination.
Baker SD et al.
Clinical Pharmacology and Therapeutics, 2009
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM et al.
Clinical Pharmacology and Therapeutics, 2008
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.
Anabtawi N et al.
Expert Opinion on Drug Metabolism & Toxicology, 0
Select a paper to view details